

MC-38细胞系

[下载为PDF](#)

- 14 次围观

产品图片



产品英文名称

[MC-38 Cell Line](#)

产品别名

[Kerafast独特的生物试剂](#)

货号/SKU

ENH204-FP

货号/规格

1 vial

库存与交货期

1-2周

人民币价格

16795

人民币价格说明

本商品人民币2024年销售价格正在调整中，请等待更新完毕。

本商品的展示的人民币价格已包含商品本身金额、VAT增值税13%、国际运输运费、国内物流运费、运输保险、以及冷链包装材料（例如液氮罐、泡沫箱、金属桶、蓝冰、湿冰、干冰、蓄冷剂、液氮等）、装卸费、相关资料费、人力支出等一切费用。

本商品的美元价、市场价、零售价、厂商指导价或该商品的曾经展示过的销售价等，并非商品原价，仅供参考。

试剂海关审批

使用人负责A/B风险申请资质

国外采购

支持/部分需签MTA

厂牌

Kerafast, Inc.

品牌

[Kerafast®](#)

产品基础信息

James W. Hodge, PhD, MBANational Cancer Institute/NIH

产品描述信息

Product Type:

Cell Line

Name: MC-38
Accession ID: CVCL_B288

Organism: C57BL6 murine
Source: Colon Carcinoma
Morphology: Epithelial
Biosafety Level: BSL1
Subculturing: 1:5 to 1:10
Growth Conditions: Dulbecco's modified MEM with 10% fetal bovine serum, 2mM glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 10 mM HEPES, 50ug/ml gentamycin sulfate, pen/strep.
Cryopreservation: 90% FBS, 10% DMSO
Mycoplasma Tested: Yes; Also tested for mouse pathogens (See: MC-38 Pathogen Testing Results)
Storage: Liquid nitrogen
Shipped: Dry ice

产品安全信息

Roh-Johnson M, Shah AN, Stonick JA, Poudel KR, Kargl J, Yang GH, di Martino J, Hernandez RE, Gast CE, Zarour LR, Antoku S, Houghton AM, Bravo-Cordero JJ, Wong MH, Condeelis J, Moens CB. Macrophage-Dependent Cytoplasmic Transfer during Melanoma Invasion In Vivo. *Dev Cell*. 2017 Dec 4;43(5):549-562.e6. View ArticleObermajer N, Urban J, Wieckowski E, Muthuswamy R, Ravindranathan R, Bartlett DL, Kalinski P. Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. *Nat Protoc*. 2018 Feb;13(2):335-357. View ArticleXiao Q, Wu J, Wang WJ, Chen S, Zheng Y, Yu X, Meeth K, Sahraei M, Bothwell ALM, Chen L, Bosenberg M, Chen J, Sexl V, Sun L, Li L, Tang W, Wu D. DKK2 imparts tumor immunity evasion through β -catenin-independent suppression of cytotoxic immune-cell activation. *Nat Med*. 2018 Mar;24(3):262-270. View ArticleVillarreal DO, L'Huillier A, Armington S, Mottershead C, Filippova EV, Coder BD, Petit RG, Princiotta MF. Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer. *Cancer Res*. 2018 Jul 19. pii: canres.1119.2018. View ArticleGrasselly C, Denis M, Bourguignon A, Talhi N, Mathe D, Tourette A, Serre L, Jordheim LP, Matera EL, Dumontet C. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. *Front Immunol*. 2018 Oct 9;9:2100. View ArticleYuzhalin AE, Gordon-Weeks AN, Tognoli ML, Jones K, Markelc B, Konietzny R, Fischer R, Muth A, O'Neill E, Thompson PR, Venables PJ, Kessler BM, Lim SY, Muschel RJ. Colorectal cancer liver metastatic growth depends on PAD4-driven citrullination of the extracellular matrix. *Nat Commun*. 2018 Nov 14;9(1):4783. View ArticlePaauwe M, Schoonderwoerd MJA, Helderma R, Harryvan TJ, Groenewoud A, van Pelt GW, Bor R, Hemmer DM, Versteeg HH, Snaar-Jagalska BE, Theuer CP, Hardwick JCH, Sier CFM, Ten Dijke P, Hawinkels LJAC. Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis. *Clin Cancer Res*. 2018 Dec 15. View ArticleChang J, Bhasin SS, Bielenberg DR, Sukhatme VP, Bhasin M, Huang S, Kieran MW, Panigrahy D. Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. *FASEB J*. 2019 Jan;33(1):114-125. View ArticleLee LYW, Woolley C, Starkey T, Biswas S, Mirshahi T, Bardella C, Segditsas S, Irshad S, Tomlinson I. Serum- and Glucocorticoid-induced Kinase Sgk1 Directly Promotes the Differentiation of Colorectal Cancer Cells and Restrains Metastasis. *Clin Cancer Res*. 2019 Jan 15. View ArticleTeng Y, Ren Y, Sayed M, Hu X, Lei C, Kumar A, Hutchins E, Mu J, Deng Z, Luo C, Sundaram K, Sriwastva MK, Zhang L, Hsieh M, Reiman R, Haribabu B, Yan J, Jala VR, Miller DM, Van Keuren-Jensen K, Merchant ML, McClain CJ, Park JW, Egilmez NK, Zhang HG. Plant-Derived Exosomal MicroRNAs Shape the Gut Microbiota. *Cell Host Microbe*. 2018 Nov 14;24(5):637-652.e8. View ArticleChen J, López-Moyado IF, Seo H, Lio CJ, Hempleman LJ, Sekiya T, Yoshimura A, Scott-Browne JP, Rao A. NR4A transcription factors limit CAR T cell function in solid tumours. *Nature*. 2019 Mar;567(7749):530-534. View ArticleYanagitani N, Friboulet L, Nishio M, Takeuchi K, Kawamoto H, Fujita N, Katayama R. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. *J Exp Med*. 2019 Apr 1;216(4):982-1000. View ArticleCao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. *Nat Commun*. 2019 Mar 20;10(1):1280. View ArticleWang W, Yang J, Edin ML, Wang Y, Luo Y, Wan D, Yang H, Song CQ, Xue W, Sanidad KZ, Song M, Bisbee HA, Bradbury JA, Nan G, Zhang J, Shih PB, Lee KSS, Minter LM, Kim D, Xiao H, Liu JY, Hammock BD, Zeldin DC, Zhang G. Targeted Metabolomics Identifies the Cytochrome P450 Monooxygenase Eicosanoid Pathway as a Novel Therapeutic Target of Colon Tumorigenesis. *Cancer Res*. 2019 Apr 15;79(8):1822-1830. View ArticleKvarnhammar AM, Veitonmäki N, Hägerbrand K, Dahlman A, Smith KE, Fritzell S, von Schantz L, Thagesson M, Werchau D, Smedenfors K, Johansson M, Rosén A, Åberg I, Winnerstam M, Nyblom E, Barchan K, Furebring C, Norlén P, Ellmark P. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. *J Immunother Cancer*. 2019 Apr 11;7(1):103. View ArticleXie YJ, Dougan M, Jaikhani N, Ingram J, Fang T, Kummer L, Momin N, Pishesha

N, Rickelt S, Hynes RO, Ploegh H. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. *Proc Natl Acad Sci U S A*. 2019 Apr 16;116(16):7624-7631. View ArticleLee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X, Black TA, Chien AL, Majmundar KS, Thompson JC, Yee SS, O'Hara MH, Aggarwal C, Xin D, Shaked A, Gao M, Liu D, Borad MJ, Ramanathan RK, Carpenter EL, Ji A, de Beer MC, de Beer FC, Webb NR, Beatty GL. Hepatocytes direct the formation of a pro-metastatic niche in the liver. *Nature*. 2019 Mar;567(7747):249-252. View ArticleSegovia M, Russo S, Jeldres M, Mahmoud YD, Perez V, Duhalde M, Charnet P, Rousset M, Victoria S, Veigas F, Louvet C, Vanhove B, Floto RA, Anegon I, Cuturi MC, Girotti MR, Rabinovich GA, Hill M. Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. *Cancer Cell*. 2019 May 13;35(5):767-781.e6. View ArticlePai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. *Immunity*. 2019 Feb 19;50(2):477-492.e8. View ArticleNakanishi Y, Duran A, L'Hermitte A, Shelton PM, Nakanishi N, Reina-Campos M, Huang J, Soldevila F, Baaten BJG, Tauriello DVF, Castilla EA, Bhangoo MS, Bao F, Sigal D, Diaz-Meco MT, Moscat J. Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunovigilance. *Immunity*. 2018 Dec 18;49(6):1132-1147.e7. View ArticleWhitehead MWJ, Khanzhin N, Borsig L, Hennet T. Custom Glycosylation of Cells and Proteins Using Cyclic Carbamate-Derivatized Oligosaccharides. *Cell Chem Biol*. 2017 Nov 16;24(11):1336-1346.e3. View ArticleTavazoie MF, Pollack I, Tanquero R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, Takeda S, Tafreshian KN, Rowinsky E, Szarek M, Waltzman RJ, Mcmillan EA, Zhao C, Mita M, Mita A, Chmielowski B, Postow MA, Ribas A, Mucida D, Tavazoie SF. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. *Cell*. 2018 Feb 8;172(4):825-840.e18. View ArticlePan WW, Moroishi T, Koo JH, Guan KL. Cell type-dependent function of LATS1/2 in cancer cell growth. *Oncogene*. 2019 Apr;38(14):2595-2610. View ArticleRabin-Court A, Rodrigues MR, Zhang XM, Perry RJ. Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation. *PLoS One*. 2019 Jun 12;14(6):e0218126. View ArticleHu Z, Qu G, Yu X, Jiang H, Teng XL, Ding L, Hu Q, Guo X, Zhou Y, Wang F, Li HB, Chen L, Jiang J, Su B, Liu J, Zou Q. Acylglycerol Kinase Maintains Metabolic State and Immune Responses of CD8(+) T Cells. *Cell Metab*. 2019 Jun 11. pii: S1550-4131(19)30256-6. View ArticleHerbst EB, Unnikrishnan S, Klivanov AL, Mauldin FW Jr, Hossack JA. Validation of Normalized Singular Spectrum Area as a Classifier for Molecularly Targeted Microbubble Adherence. *Ultrasound Med Biol*. 2019 Jun 18. pii: S0301-5629(19)30236-4. View ArticleGong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, Besse B, Yanagitani N, Friboulet L, Nishio M, Takeuchi K, Kawamoto H, Fujita N, Katayama R. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. *J Exp Med*. 2019 Apr 1;216(4):982-1000. View ArticleEkiz HA, Lai SA, Gundlapalli H, Haroun F, Williams MA, Welm AL. Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth. *Oncoimmunology*. 2018 Jul 11;7(9):e1480286. View ArticleXu YP, Lv L, Liu Y, Smith MD, Li WC, Tan XM, Cheng M, Li Z, Bovino M, Aubé J, Xiong Y. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. *J Clin Invest*. 2019 Jul 16;130. View ArticleOu W, Byeon JH, Thapa RK, Ku SK, Yong CS, Kim JO. Plug-and-Play Nanorization of Coarse Black Phosphorus for Targeted Chemophotoimmunotherapy of Colorectal Cancer. *ACS Nano*. 2018 Oct 23;12(10):10061-10074. doi: 10.1021/acsnano.8b04658. Epub 2018 Sep 19. View ArticleLarimer BM, Bloch E, Nesti S, Austin EE, Wehrenberg-Klee E, Boland G, Mahmood U. The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. *Clin Cancer Res*. 2019 Feb 15;25(4):1196-1205. View ArticleLeclerc M, Voilin E, Gros G, Cognac S, de Montpréville V, Validire P, Bismuth G, Mami-Chouaib F. Regulation of antitumor CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. *Nat Commun*. 2019 Jul 26;10(1):3345. doi: 10.1038/s41467-019-11280-z. View ArticleTanegashima T, Togashi Y, Azuma K, Kawahara A, Ideguchi K, Sugiyama D, Kinoshita F, Akiba J, Kashiwagi E, Takeuchi A, Irie T, Tatsugami K, Hoshino T, Eto M, Nishikawa H. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. *Clin Cancer Res*. 2019 May 10. View ArticlePhan T, Nguyen VH, D'Alincourt MS, Manuel ER, Kaltcheva T, Tsai W, Blazar BR, Diamond DJ, Melstrom LG. Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. *Cancer Gene Ther*. 2019 Mar 1. View ArticleGarrido G, Schrand B, Rabasa A, et al. Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity. *Nat Commun*. 2019;10(1):3773. Published 2019 Aug 21. View ArticleBae T, Jang J, Lee H, et al. Paeonia lactiflora root extract suppresses cancer cachexia by down-regulating muscular NF- κ B signalling and muscle-specific E3 ubiquitin ligases in cancer-bearing mice. *J Ethnopharmacol*. 2020;246:112222. View articleSivakumar R, Chan M, Shin JS, et al. Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. *Oncoimmunology*. 2019;8(12):e1670019. Published 2019 Oct 10. View articleKusano T, Ehrichiou D, Matsumura T, et al. Targeted knock-in mice expressing the oxidase-fixed form of xanthine oxidoreductase favor tumor growth. *Nat Commun*. 2019;10(1):4904. Published 2019 Oct 28. View articleYokoyama Y, Lew ED, Seelige R, et al. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor. *Cancer Res*. 2019;79(8):1996-2008. View articleNasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ. SGLT2 inhibition slows tumor growth in mice by

reversing hyperinsulinemia. *Cancer Metab.* 2019;7:10. Published 2019 Dec 11. View article

Dinarvand P, Yang L, Biswas I, Giri H, Rezaie AR. Plasmodium falciparum histidine rich protein HRP11 inhibits the anti-inflammatory function of antithrombin. *J Thromb Haemost.* 2020;18(6):1473-1483. View article

Ho WJ, Yarchoan M, Charmsaz S, et al. Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodes. *JCI Insight.* 2020;5(2):e132286. Published 2020 Jan 30. View article

Strauss L, Mahmoud MAA, Weaver JD, et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. *Sci Immunol.* 2020;5(43):eaay1863. View article

Scortegagna M, Hockemeyer K, Dolgalev I, et al. Siah2 control of T-regulatory cells limits anti-tumor immunity. *Nat Commun.* 2020;11(1):99. Published 2020 Jan 7. View article

Yu M, Guo G, Huang L, et al. CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint. *Nat Commun.* 2020;11(1):515. Published 2020 Jan 24. View article

Sugiyama E, Togashi Y, Takeuchi Y, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. *Sci Immunol.* 2020;5(43):eaav3937. View article

Scheetz LM, Yu M, Li D, Castro MG, Moon JJ, Schwendeman A. Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma. *Int J Mol Sci.* 2020;21(5):1777. Published 2020 Mar 5. View article

Wang G, Kang X, Chen KS, et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. *Nat Commun.* 2020;11(1):1395. Published 2020 Mar 13. View article

Zhao R, Xiao Q, Li M, et al. Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy. *Antib Ther.* 2020;3(2):63-70. View article

Guan Y, Kraus SG, Quaney MJ, Daniels MA, Mitchem JB, Teixeira E. FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer. *Front Oncol.* 2020;10:586. Published 2020 Apr 23. View article

Waschkies CF, Pfiffner FK, Heuberger DM, et al. Tumor grafts grown on the chicken chorioallantoic membrane are distinctively characterized by MRI under functional gas challenge. *Sci Rep.* 2020;10(1):7505. Published 2020 May 5. View article

Hu J, Wang Z, Chen Z, et al. DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer. *Biomed Pharmacother.* 2020;127:110229. View article

LaSalle T, Austin EE, Rigney G, et al. Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response. *J Immunother Cancer.* 2020;8(1):e000291. View article

Buss CG, Bhatia SN. Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics. *Proc Natl Acad Sci U S A.* 2020;117(24):13428-13436. View article

Grant FM, Yang J, Nasrallah R, et al. BACH2 drives quiescence and maintenance of resting Treg cells to promote homeostasis and cancer immunosuppression. *J Exp Med.* 2020;217(9):e20190711. View article

Strauss L, Mahmoud MAA, Weaver JD, et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. *Sci Immunol.* 2020;5(43):eaay1863. View article

Kumagai S, Togashi Y, Sakai C, et al. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. *Immunity.* 2020;53(1):187-203.e8. View article

Muramatsu T, Noguchi T, Sugiyama D, et al. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T cell-dependent manner [published online ahead of print, 2020 Jul 30]. *Int Immunol.* 2020;dxaa049. View article

Nagasaki J, Togashi Y, Sugawara T, Itami M, Yamauchi N, Yuda J, Sugano M, Ohara Y, Minami Y, Nakamae H, Hino M, Takeuchi M, Nishikawa H. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. *Blood Adv.* 2020 Sep 8;4(17):4069-4082. View article

Ou P, Wen L, Liu X, Huang J, Huang X, Su C, Wang L, Ni H, Reizis B, Yang CY. Thioesterase PPT1 balances viral resistance and efficient T cell crosspriming in dendritic cells. *J Exp Med.* 2019 Sep 2;216(9):2091-2112. View article

Ou W, Byeon JH, Soe ZC, Kim BK, Thapa RK, Gupta B, Poudel BK, Ku SK, Yong CS, Kim JO. Tailored Black Phosphorus for Erythrocyte Membrane Nanocloaking with Interleukin-1 α siRNA and Paclitaxel for Targeted, Durable, and Mild Combination Cancer Therapy. *Theranostics.* 2019 Sep 19;9(23):6780-6796. View article

Yuzhalin AE, Lim SY, Gordon-Weeks AN, Fischer R, Kessler BM, Yu D, Muschel RJ. Proteomics analysis of the matrisome from MC38 experimental mouse liver metastases. *Am J Physiol Gastrointest Liver Physiol.* 2019 Nov 1;317(5):G625-G639. View article

Hsu TS, Lin YL, Wang YA, Mo ST, Chi PY, Lai AC, Pan HY, Chang YJ, Lai MZ. HIF-2 α is indispensable for regulatory T cell function. *Nat Commun.* 2020 Oct 6;11(1):5005. View article

Fernandes RA, Su L, Nishiga Y, Ren J, Bhuiyan AM, Cheng N, Kuo CJ, Picton LK, Ohtsuki S, Majzner RG, Rietberg SP, Mackall CL, Yin Q, Ali LR, Yang X, Savvides CS, Sage J, Dougan M, Garcia KC. Immune receptor inhibition through enforced phosphatase recruitment. *Nature.* 2020 Oct;586(7831):779-784. View article

Jacobs L, De Smidt E, Geukens N, Declerck P, Hollevoet K. Electroporation outperforms in vivo-jetPEI for intratumoral DNA-based reporter gene transfer. *Sci Rep.* 2020 Nov 11;10(1):19532. View article

Cho R, Sakurai Y, Jones HS, Akita H, Hisaka A, Hatakeyama H. Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors. *Cancers (Basel).* 2020 Dec 4;12(12):E3630. View article

Luo R, Firat E, Gaedicke S, Guffart E, Watanabe T, Niedermann G. Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment. *Clin Cancer Res.* 2019 Dec 1;25(23):7243-7255. View article

Capietto AH, Jhunjhunwala S, Pollock SB, Lupardus P, Wong J, Hänsch L, Cevallos J, Chestnut Y, Fernandez A, Lounsbury N, Nozawa T, Singh M, Fan Z, de la Cruz CC, Phung QT, Taraborrelli L, Haley B, Lill JR, Mellman I, Bourgon R, Delamarre L. Mutation position is an important determinant for predicting cancer neoantigens. *J Exp Med.* 2020 Apr 6;217(4):e20190179. View article

Karagiannidis I, Jerman SJ, Jacenik D, Phinney BB, Yao R, Prossnitz ER, Beswick EJ. G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor

Growth and Are Potential Therapeutic Targets. *Front Immunol.* 2020 Sep 15;11:1885. View articleMittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall VLJ, Liu C, Bettington ML, Takeda K, Long GV, Scolyer RA, Lan R, Siemers N, Korman A, Teng MWL, Johnston RJ, Dougall WC, Smyth MJ. CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. *Cancer Immunol Res.* 2019 Apr;7(4):559-571.View articleMyers DR, Abram CL, Wildes D, Belwafa A, Welsh AMN, Schulze CJ, Choy TJ, Nguyen T, Omaque N, Hu Y, Singh M, Hansen R, Goldsmith MA, Quintana E, Smith JAM, Lowell CA. Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity. *Front Immunol.* 2020 Sep 29;11:576310.View articleTrillo-Tinoco J, Sierra RA, Mohamed E, Cao Y, de Mingo-Pulido Á, Gilvary DL, Anadon CM, Costich TL, Wei S, Flores ER, Ruffell B, Conejo-Garcia JR, Rodriguez PC. AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells. *Cancer Res.* 2019 Oct 1;79(19):5034-5047.View articleKohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, Lasater EA, Shi Y, Dave N, Riehm JJ, Robinson VA, Do AD, Li Y, Orr CJ, Sampath D, Raval A, Merchant M, Bhathena A, Salem AH, Hamel KM, Levenson JD, Donawho C, Pappano WN, Uziel T. Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. *Cancer Discov.* 2020 Sep 4.View articleMagiera-Mularz K, Kocik J, Musielak B, Plewka J, Sala D, Machula M, Grudnik P, Hajduk M, Czepiel M, Siedlar M, Holak TA, Skalniak L. Human and mouse PD-L1: similar molecular structure, but different druggability profiles. *iScience.* 2020 Dec 24;24(1):101960.View articleBudhu S, Giese R, Gupta A, Fitzgerald K, Zappasodi R, Schad S, Hirschhorn D, Campesato LF, De Henau O, Gigoux M, Liu C, Mazo G, Deng L, Barker CA, Wolchok JD, Merghoub T. Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. *Cell Rep.* 2021 Jan 12;34(2):108620.View articleYou G, Lee Y, Kang YW, Park HW, Park K, Kim H, Kim YM, Kim S, Kim JH, Moon D, Chung H, Son W, Jung UJ, Park E, Lee S, Son YG, Eom J, Won J, Park Y, Jung J, Lee SW. B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes. *Sci Adv.* 2021 Jan 15;7(3):eaax3160.View articleYang SB, Lee MH, Kim BR, Choi YM, Kim BJ. A Hepatitis B Virus-Derived Peptide Exerts an Anticancer Effect via TNF/iNOS-producing Dendritic Cells in Tumor-Bearing Mouse Model. *Cancers (Basel).* 2021 Jan 22;13(3):407. View articleGhonim MA, Ibba SV, Tarhuni AF, Errami Y, Luu HH, Dean MJ, El-Bahrawy AH, Wyczechowska D, Benslimane IA, Del Valle L, Al-Khami AA, Ochoa AC, Boulares AH. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer. *J Immunother Cancer.* 2021 Jan;9(1):e001643.View articleVilla A, Garofalo M, Crescenti D, Rizzi N, Brunialti E, Vingiani A, Belotti P, Sposito C, Franzè S, Cilurzo F, Pruneri G, Recordati C, Giudice C, Giordano A, Tortoreto M, Beretta G, Stefanello D, Manenti G, Zaffaroni N, Mazzaferro V, Ciana P. Transplantation of autologous extracellular vesicles for cancer-specific targeting. *Theranostics.* 2021 Jan 1;11(5):2034-2047. View articleRodriguez-Garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, O'Connor RS, Minutolo NG, Casado-Medrano V, Lopez G, Matsuyama T, Powell DJ Jr. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. *Nat Commun.* 2021 Feb 9;12(1):877. View articleLewis ND, Sia CL, Kirwin K, Haupt S, Mahimkar G, Zi T, Xu K, Dooley K, Jang SC, Choi B, Boutin A, Grube A, McCoy C, Sanchez-Salazar J, Doherty M, Gaidukov L, Estes S, Economides KD, Williams DE, Sathyanarayanan S. Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12. *Mol Cancer Ther.* 2020 Dec 21. View articleFan J, Das JK, Xiong X, Chen H, Song J. Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors. *Front Oncol.* 2021 Jan 6;10:574860.View articleChoi YW, Kim YH, Oh SY, Suh KW, Kim YS, Lee GY, Yoon JE, Park SS, Lee YK, Park YJ, Kim HS, Park SH, Kim JH, Park TJ. Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer. *Adv Sci (Weinh).* 2021 Jan 4;8(4):2002497. View articleYoon Y, Kim G, Jeon BN, Fang S, Park H. Bifidobacterium Strain-Specific Enhances the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice. *Cancers (Basel).* 2021 Feb 25;13(5):957. View articleCharmsaz S, Gross N, Jaffee E, Ho WJ. A global live cell barcoding approach for multiplexed mass cytometry profiling of mouse tumors. *JCI Insight.* 2021 Apr 8;6(7):143283.View articlePrakash MD, Stojanovska L, Feehan J, Nurgali K, Donald EL, Plebanski M, Flavel M, Kitchen B, Apostolopoulos V. Anti-cancer effects of polyphenol-rich sugarcane extract. *PLoS One.* 2021 Mar 10;16(3):e0247492.View articleLione L, Salvatori E, Petrazzuolo A, Massacci A, Maggio R, Confroti A, Compagnone M, Aurisicchio L, Ciliberto G, Palombo F. Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition. *Oncoimmunology.* 2021 Mar 23;10(1):1898832.View articleBahmani B, Gong H, Luk BT, Haushalter KJ, DeTeresa E, Previti M, Zhou J, Gao W, Bui JD, Zhang L, Fang RH, Zhang J. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. *Nat Commun.* 2021 Mar 31;12(1):1999. View articlePeled M, Bar-Lev TH, Talalai E, Aspitz HZ, Daniel-Meshulam I, Bar J, Kamer I, Ofek E, Mor A, Onn A. Mesencephalic astrocyte-derived neurotrophic factor is secreted from interferon-γ-activated tumor cells through ER calcium depletion. *PLoS One.* 2021 Apr 23;16(4):e0250178. View articleIf you publish research with this product, please let us know so we can cite your paper.

主要内容

MC-38衍生自C57BL6鼠结肠腺癌细胞。从詹姆斯W. Hodge, Phd, MBA和Jeffrey Schlom, Phd, 国家癌症学院/NIH的实验室。

厂牌介绍

关于Kerafast Inc.

Kerafast 是一家位于波士顿的试剂公司，其主要使命是为QuanQiu科学界提供易于使用的独特实验室研究工具。我们的产品组合包括细胞系、抗体、小分子、染料等，其中许多在其他地方无法获得。自 2011 年成立以来，来自全球 190 多个机构的研究人员通过我们的在线平台提供了他们的创新试剂，无需通过传统的材料转让协议流程即可快速获取材料。

我们处理提供实验室的所有销售和运输物流，并从每次销售中返还丰厚的特许权使用费。因此，我们帮助提供实验室节省时间和资源，同时为进一步研究提供额外资金。采购科学家可以更轻松地发现和获取其他地方通常无法获得的独特试剂，同时还可以资助其他研究人员的工作。这创建了一个QuanQiu科学家社区，他们贡献和获取Reagent for the Greater Good，以加速他们自己的研究以及整体科学进步。

2018 年，Kerafast 与Absolute Antibody合并，后者是一家总部位于英国的公司，其愿景是为所有研究人员提供重组抗体技术。此次合并将两家公司聚集在一起，共同致力于改善科学界可用的研究工具的选择。

品牌标识



产品关键词

- [kerafast抗体ED2003](#)
- [kerafast 抗体](#)
- [kerafast国内代理商](#)
- [kerafast](#)
- [kerafast 代理](#)
- [kerafast细胞](#)
- [kerafast抗体代理](#)
- [kerafast代理商](#)
- [kerafast品牌](#)
- [kerafast代理](#)
- [kerafast细胞代购kerafast品牌代理](#)
- [kerafast华北代理](#)
- [美国kerafast公司](#)
- [kerafast公司](#)
- [进口kerafast代理](#)
- [kerafast丁香通](#)
- [kerafast中国代理](#)
- [kerafast官网](#)
- [kerafast抗体](#)
- [kerafast专业代理](#)

一键获取大包装优惠报价

- 无 -

选择您的报价场景

- 【我们直接使用】需要优惠报价、大包装规格、货期 -- ---->[报价默认含增值税13%发票；尽量提供货号、规格、需求数量]
- 【需要技术文档】产品说明书、COA、MSDS、手册 -- ---->[默认提供说明书或者COA，特别技术指标要求请下面填入详细描述]
- 【我帮客户找货】需要优惠报价、大包装规格、货期 -- ---->[报价默认含增值税13%发票]
- 【推荐替代产品】需要优惠报价、大包装规格、货期 -- ---->[提供替代产品的价格，默认含增值税13%发票]
- 【我能原厂直采】请只提供代理进口清关服务的报价 -- ---->[适合只需要进口许可证代办服务、清关服务的专业级买家，独立服务]
- 【其它报价场景】

请输入您的情况与报价要求

报价要求详细描述

贵单位贵姓

接受报价的E-mail

手机扫描二维码阅读本页





可能感兴趣的内容

[HM-34柠檬酸杆菌属,30_2\(细菌\)](#)

2022-04-01

[道康宁DC184 SYLGARD 184灌封胶PDMS 110g](#)

2021-12-02

[NR-13472结核分枝杆菌,CDC1551TransposonMutant34\(MT1862,Rv1814\)\(突变细菌\)](#)

2022-04-01

[NR-22091 肠沙门氏菌,SerovarNewport,分离物S8949\(细菌\)](#)

2022-04-01

[专家提出噬菌体防御系统基因的影响应引起重视](#)

2022-06-17

[MRA-742chabaudichabaudi疟原虫,AS\(3CO\)\(寄生原动物\)](#)

2022-04-01

[NR-28911来自成年雌性曼氏血吸虫的基因组DNA,菌株NMRI\(核酸\)](#)

2022-04-01

[NR-3228多克隆抗仙台病毒,\(抗血清,豚鼠\)\(多克隆抗血清\)](#)

2022-03-31

[NR-46819金黄色葡萄球菌亚种.金黄色葡萄球菌,USA300JE2,转座子突变体SAUSA300_0293\(NE276\)\(突变体细菌\)](#)

2022-04-01

[NR-42566 晚期免疫性乙型脑炎病毒抗血清\(多克隆抗血清\)](#)

2022-04-01

[呼肠孤病毒\(REO\) FITC共轭物1毫升](#)

2019-05-08

[抗CD63 \[ME491\]抗体](#)

2021-12-21

[NR-50234 寨卡病毒,PLCal_ZV?\(人类/2013/泰国\)\(病毒\)](#)

2022-04-01

[研究揭示隐藻的光适应与捕光调节机制](#)

2024-08-19

[NR-10133金黄色葡萄球菌,TCH1516\(细菌\)](#)

2022-04-01

[NR-3976多克隆抗黄斑支原体,PG-15,\(抗血清,驴\)\(多克隆抗血清\)](#)

2022-03-31

[NR-48130金黄色葡萄球菌亚种.金黄色葡萄球菌,USA300JE2,转座子突变体SAUSA300_1783\(NE1588\)\(突变细菌\)](#)

2022-04-01

[NR-29036 甲型流感病毒,A/PuertoRico/8-CV9/1934\(H1N1\)\(病毒\)](#)

2022-04-01

[NR-38044型登革热病毒,D85-019\(病毒\)](#)

2022-03-31

[NR-47063金黄色葡萄球菌亚种金黄色葡萄球菌、JE2、转座子突变体NE520\(SAUSA300_1452\)\(突变细菌\)](#)

2022-04-01